Analysts’ Recent Ratings Changes for Gilead Sciences (GILD)

Several analysts have recently updated their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

  • 12/4/2018 – Gilead Sciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/1/2018 – Gilead Sciences was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/21/2018 – Gilead Sciences was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/21/2018 – Gilead Sciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 11/14/2018 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 11/14/2018 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 11/8/2018 – Gilead Sciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/1/2018 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Raymond James.
  • 11/1/2018 – Gilead Sciences was given a new $94.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 10/31/2018 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Evercore ISI.
  • 10/26/2018 – Gilead Sciences had its price target lowered by analysts at Raymond James from $97.00 to $94.00. They now have a “strong-buy” rating on the stock.
  • 10/26/2018 – Gilead Sciences had its price target raised by analysts at Barclays PLC from $90.00 to $95.00. They now have an “overweight” rating on the stock.
  • 10/26/2018 – Gilead Sciences had its price target raised by analysts at Cantor Fitzgerald from $87.00 to $88.00. They now have an “overweight” rating on the stock. They wrote, “: We are increasing our price target to $88 from $87 and reiterating our Overweight rating. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV. Our price target is higher by $1/share given revenue trends were slightly more robust than we projected. The company also increased its product revenue guidance to $20.8-21.3B from $20-21B. Product revenues were $5.45B and EPS were $1.84/share. Biktarvy beat expectations by ~$50M, as it reported revenues of $375M. GILD has also benefited from a generic Letairis not entering the market, and it doesn’t expect an entrant in 2018. We have updated our estimates for the quarter.””
  • 10/26/2018 – Gilead Sciences was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating. They now have a $75.00 price target on the stock, down previously from $85.00.
  • 10/26/2018 – Gilead Sciences was given a new $94.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 10/24/2018 – Gilead Sciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/11/2018 – Gilead Sciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of GILD stock traded down $2.04 on Friday, reaching $68.15. 5,643,743 shares of the company were exchanged, compared to its average volume of 7,342,123. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54. The stock has a market capitalization of $89.97 billion, a P/E ratio of 7.96, a P/E/G ratio of -2.70 and a beta of 1.01. The company has a quick ratio of 3.37, a current ratio of 3.45 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The company had revenue of $5.60 billion during the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same quarter in the prior year, the company earned $2.27 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be issued a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.35%. Gilead Sciences’s payout ratio is 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $69.55, for a total transaction of $3,477,500.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at approximately $213,362,847.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders sold 150,000 shares of company stock worth $10,939,500. Company insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Gilead Sciences during the 3rd quarter worth $100,000. Reilly Financial Advisors LLC boosted its stake in Gilead Sciences by 98.3% during the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Gilead Sciences during the 2nd quarter worth $132,000. Brand Asset Management Group Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth $139,000. Finally, TRUE Private Wealth Advisors acquired a new stake in Gilead Sciences during the 3rd quarter worth $174,000. 78.19% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: Fundamental Analysis and Individual Investors

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply